AAV-mediated gene therapy for liver diseases: The prime candidate for clinical application?

Expert Opinion on Biological Therapy

Volumn 11, Issue 3, 2011, Pages 315-327

  Van Der Laan, Luc J W ^a   Wang, Yigang ^b   Tilanus, Hugo W ^a   Janssen, Harry L A ^a   Pan, Qiuwei ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b ZHEJIANG SCI TECH UNIVERSITY   (China)

Author keywords

AAV; adeno associated virus; hemophilia; hepatic delivery; hepatic gene therapy; RNAi; serotypes; viral vector

Indexed keywords

ADENOVIRUS VECTOR; CYCLOSPORIN A; DACLIZUMAB; DEXAMETHASONE; DOUBLE STRANDED DNA; GENE THERAPY AGENT; MICRORNA; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; RAPAMYCIN; SINGLE STRANDED DNA; TACROLIMUS; THYMOCYTE ANTIBODY;

ADENOVIRUS; CRIGLER NAJJAR SYNDROME; DNA SYNTHESIS; FAMILIAL HYPERCHOLESTEROLEMIA; GENE EXPRESSION; GENE THERAPY; GOOD MANUFACTURING PRACTICE; HEMOPHILIA A; HEMOPHILIA B; HEPATITIS B; HEPATITIS C; HUMAN; HUMORAL IMMUNITY; IMMUNOSUPPRESSIVE TREATMENT; LIVER CELL CARCINOMA; LIVER DISEASE; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; NONHUMAN; REVIEW; RNA INTERFERENCE; SEROTYPING; SEVERE COMBINED IMMUNODEFICIENCY; VIRAL GENE DELIVERY SYSTEM; VIRUS CAPSID;

ANIMALS; DEPENDOVIRUS; GENE THERAPY; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; HUMANS; LIVER DISEASES; TREATMENT OUTCOME;

ADENO-ASSOCIATED VIRUS; ANIMALIA;

EID: 79851480011     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.2011.548799     Document Type: Review

References (156)

1. Muzyczka N, Samulski RJ, Hermonat P, et al. The genetics of adeno-associated virus. Adv Exp Med Biol 1984;179:151-61
2. Goncalves MA. Adeno-associated virus: from defective virus to effective vector. Virol J 2005;2:43
3. McCarty DM, Young SM Jr, Samulski RJ. Integration of adeno-associated virus (AAV) and recombinant AAV vectors. Annu Rev Genet 2004;38:819-45 (Pubitemid 40013747)
4. Wu Z, Asokan A, Samulski RJ. Adeno-associated virus serotypes: vector toolkit for human gene therapy. Mol Ther 2006;14:316-27 (Pubitemid 44184972)
5. Ohi S, Dixit M, Tillery MK, et al. Construction and replication of an adeno-associated virus expression vector that contains human beta-globin cDNA. Gene 1990;89:279-82 (Pubitemid 20206211)
6. Gao GP, Alvira MR, Wang L, et al. Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy. Proc Natl Acad Sci USA 2002;99:11854-9 (Pubitemid 34994488)
7. Nakai H, Fuess S, Storm TA, et al. Unrestricted hepatocyte transduction with adeno-associated virus serotype 8 vectors in mice. J Virol 2005;79:214-24 (Pubitemid 39650967)
8. Nakai H, Storm TA, Kay MA. Recruitment of single-stranded recombinant adeno-associated virus vector genomes and intermolecular recombination are responsible for stable transduction of liver in vivo. J Virol 2000;74:9451-63
9. Ferrari FK, Samulski T, Shenk T, et al. Second-strand synthesis is a rate-limiting step for efficient transduction by recombinant adeno-associated virus vectors. J Virol 1996;70:3227-34 (Pubitemid 26121941)
10. Fisher KJ, Gao GP, Weitzman MD, et al. Transduction with recombinant adeno-associated virus for gene therapy is limited by leading-strand synthesis. J Virol 1996;70:520-32 (Pubitemid 126508820)
11. Wu Z, Sun J, Zhang T, et al. Optimization of self-complementary AAV vectors for liver-directed expression results in sustained correction of hemophilia B at low vector dose. Mol Ther 2008;16:280-9 (Pubitemid 351168036)
12. Pan Q, Tilanus HW, Janssen HL, et al. Prospects of RNAi and microRNA-based therapies for hepatitis C. Expert Opin Biol Ther 2009;9:713-24
13. Wright JF. Manufacturing and characterizing AAV-based vectors for use in clinical studies. Gene Ther 2008;15:840-8 (Pubitemid 351712617)
14. Zhang H, Xie J, Xie Q, et al. Adenovirus-adeno-associated virus hybrid for large-scale recombinant adeno-associated virus production. Hum Gene Ther 2009;20:922-9
15. Xiao W, Chirmule N, Berta SC, et al. Gene therapy vectors based on adeno-associated virus type 1. J Virol 1999;73:3994-4003 (Pubitemid 29189844)
16. Lock M, Alvira M, Vandenberghe LH, et al. Rapid, simple and versatile manufacturing of recombinant adeno-associated virus vectors at scale. Hum Gene Ther 2010;21:1259-71
17. Clark KR, Voulgaropoulou F, Fraley DM, et al. Cell lines for the production of recombinant adeno-associated virus. Hum Gene Ther 1995;6:1329-41
18. Fisher KJ, Kelley WM, Burda JF, et al. A novel adenovirus-adeno- associated virus hybrid vector that displays efficient rescue and delivery of the AAV genome. Hum Gene Ther 1996;7:2079-87 (Pubitemid 26400733)
19. ConwayJE, Zolotukhin S, Muzyczka N, et al. Recombinant adeno-associated virus type 2 replication and packaging is entirely supported by a herpes simplex virus type 1 amplicon expressing Rep and Cap. J Virol 1997;71:8780-9 (Pubitemid 27446462)
20. Sollerbrant K, Elmen J, Wahlestedt C, et al. A novel method using baculovirus-mediated gene transfer for production of recombinant adeno-associated virus vectors. J Gen Virol 2001;82:2051-60 (Pubitemid 32827585)
21. Urabe M, Ding C, Kotin RM. Insect cells as a factory to produce adeno-associated virus type 2 vectors. Hum Gene Ther 2002;13:1935-43 (Pubitemid 35341035)
22. Smith RH, Levy JR, Kotin RM. A simplified baculovirus-AAV expression vector system coupled with one-step affinity purification yields high-titer rAAV stocks from insect cells. Mol Ther 2009;17:1888-96
23. Wright JF. Transient transfection methods for clinical adeno-associated viral vector production. Hum Gene Ther 2009;20:698-706
24. Blaese RM, Culver KW, Miller AD, et al. T lymphocyte-directed gene therapy for ADA-SCID: initial trial results after 4 years. Science 1995;270:475-80
25. Jenks S. Gene therapy death-"everyone has to share in the guilt". J Natl Cancer Inst 2000;92:98-100
26. Check E. A tragic setback. Nature 2002;420:116-18 (Pubitemid 35340095)
27. Friedmann T. Clinical gene therapy: lessons from the ether dome. Mol Ther 2004;10:205-6 (Pubitemid 39117864)
28. Friedmann T. A new serious adverse event in a gene therapy study. Mol Ther 2007;15:1899-900 (Pubitemid 350011725)
29. Bainbridge JW, Smith AJ, Barker SS, et al. Effect of gene therapy on visual function in Leber's congenital amaurosis. N Engl J Med 2008;358:2231-9 (Pubitemid 351724452)
30. Maguire AM, Simonelli F, Pierce EA, et al. Safety and efficacy of gene transfer for Leber's congenital amaurosis. N Engl J Med 2008;358:2240-8 (Pubitemid 351724453)
31. Cideciyan AV, Aleman TS, Boye SL, et al. Human gene therapy for RPE65 isomerase deficiency activates the retinoid cycle of vision but with slow rod kinetics. Proc Natl Acad Sci USA 2008;105:15112-17
32. Maguire AM, High KA, Auricchio A, et al. Age-dependent effects of RPE65 gene therapy for Leber's congenital amaurosis: a phase 1 dose-escalation trial. Lancet 2009;374:1597-605
33. Gene Therapy Clinical Trials Worldwide. Available from: http://www.wiley.com/legacy/wileychi/genmed/clinical/
34. Manno CS, Pierce GF, Arruda VR, et al. Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response. Nat Med 2006;12:342-7 (Pubitemid 43355084)
35. Barbera-Guillem E, Vidal-Vanaclocha F. Sinusoidal structure of the liver. Rev Biol Cell 1988;16:1-34, 54-68
36. De Leeuw AM, Brouwer A, Knook DL. Sinusoidal endothelial cells of the liver: fine structure and function in relation to age. J Electron Microsc Tech 1990;14:218-36 (Pubitemid 20090754)
37. Skandalakis JE, Skandalakis LJ, Skandalakis PN, et al. Hepatic surgical anatomy. Surg Clin North Am 2004;84:413-35, viii (Pubitemid 38388275)
38. Suda T, Liu D. Hydrodynamic gene delivery: its principles and applications. Mol Ther 2007;15:2063-9 (Pubitemid 350148920)
39. Brunetti-Pierri N, Stapleton GE, Law M, et al. Efficient, long-term hepatic gene transfer using clinically relevant HDAd doses by balloon occlusion catheter delivery in nonhuman primates. Mol Ther 2009;17:327-33
40. Grossman M, Raper SE, Kozarsky K, et al. Successful ex vivo gene therapy directed to liver in a patient with familial hypercholesterolaemia. Nat Genet 1994;6:335-41 (Pubitemid 24190015)
41. Shaked A, Csete ME, Drazan KE, et al. Adenovirus-mediated gene transfer in the transplant setting. II. Successful expression of transferred cDNA in syngeneic liver grafts. Transplantation 1994;57:1508-11 (Pubitemid 24169952)
42. OlthoffKM, Judge TA, Gelman AE, et al. Adenovirus-mediated gene transfer into cold-preserved liver allografts: survival pattern and unresponsiveness following transduction with CTLA4Ig. Nat Med 1998;4:194-200 (Pubitemid 28137374)
43. Henry SD, van der Wegen P, Metselaar HJ, et al. Hydroxyethyl starch-based preservation solutions enhance gene therapy vector delivery under hypothermic conditions. Liver Transpl 2008;14:1708-17
44. Murphy SL, High KA. Gene therapy for haemophilia. Br J Haematol 2008;140:479-87 (Pubitemid 351230073)
45. Costea I, Isasi R, Knoppers BM, et al. Haemophilia gene therapy: the patients' perspective. Haemophilia 2009;15:1159-61
46. Matrai J, Chuah MK, Vandendriessche T. Preclinical and clinical progress in hemophilia gene therapy. Curr Opin Hematol 2010;17:387-92
47. Kelley K, Verma I, Pierce GF. Gene therapy: reality or myth for the global bleeding disorders community? Haemophilia 2002;8:261-7 (Pubitemid 35277145)
48. Kay MA, Manno CS, Ragni MV, et al. Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector. Nat Genet 2000;24:257-61 (Pubitemid 30132193)
49. Powell JS, Ragni MV, White GC II, et al. Phase 1 trial of FVIII gene transfer for severe hemophilia A using a retroviral construct administered by peripheral intravenous infusion. Blood 2003;102:2038-45 (Pubitemid 37122377)
50. Roth DA, Tawa NE Jr, O'Brien JM, et al. Nonviral transfer of the gene encoding coagulation factor VIII in patients with severe hemophilia A. N Engl J Med 2001;344:1735-42 (Pubitemid 32497027)
51. Nakai H, Herzog RW, Hagstrom JN, et al. Adeno-associated viral vector-mediated gene transfer of human blood coagulation factor IX into mouse liver. Blood 1998;91:4600-7 (Pubitemid 28270308)
52. Mount JD, Herzog RW, Tillson DM, et al. Sustained phenotypic correction of hemophilia B dogs with a factor IX null mutation by liver-directed gene therapy. Blood 2002;99:2670-6 (Pubitemid 34525351)
53. Scallan CD, Lillicrap D, Jiang H, et al. Sustained phenotypic correction of canine hemophilia A using an adeno-associated viral vector. Blood 2003;102:2031-7 (Pubitemid 37122376)
54. Scallan CD, Liu T, Parker AE, et al. Phenotypic correction of a mouse model of hemophilia A using AAV2 vectors encoding the heavy and light chains of FVIII. Blood 2003;102:3919-26 (Pubitemid 37486971)
55. Sarkar R, Xiao W, Kazazian HH Jr. A single adeno-associated virus (AAV)-murine factor VIII vector partially corrects the hemophilia A phenotype. J Thromb Haemost 2003;1:220-6
56. Jiang H, Lillicrap D, Patarroyo-White S, et al. Multiyear therapeutic benefit of AAV serotypes 2, 6, and 8 delivering factor VIII to hemophilia A mice and dogs. Blood 2006;108:107-15 (Pubitemid 43990618)
57. Ishiwata A, Mimuro J, Mizukami H, et al. Liver-restricted expression of the canine factor VIII gene facilitates prevention of inhibitor formation in factor VIII-deficient mice. J Gene Med 2009;11:1020-9
58. Nathwani AC, Gray JT, McIntosh J, et al. Safe and efficient transduction of the liver after peripheral vein infusion of self-complementary AAV vector results in stable therapeutic expression of human FIX in nonhuman primates. Blood 2007;109:1414-21 (Pubitemid 46239572)
59. Herzog RW. Hepatic AAV gene transfer and the immune system: friends or foes? Mol Ther 2010;18:1063-6
60. Hobbs HH, Brown MS, Goldstein JL. Molecular genetics of the LDL receptor gene in familial hypercholesterolemia. Hum Mutat 1992;1:445-66
61. Grossman M, Rader DJ, Muller DW, et al. A pilot study of ex vivo gene therapy for homozygous familial hypercholesterolaemia. Nat Med 1995;1:1148-54
62. Kozarsky KF, McKinley DR, Austin LL, et al. In vivo correction of low density lipoprotein receptor deficiency in the watanabe heritable hyperlipidemic rabbit with recombinant adenoviruses. J Biol Chem 1994;269:13695-702 (Pubitemid 24206152)
63. Chen SJ, Rader DJ, Tazelaar J, et al. Prolonged correction of hyperlipidemia in mice with familial hypercholesterolemia using an adeno-associated viral vector expressing very-low-density lipoprotein receptor. Mol Ther 2000;2:256-61
64. Nomura S, Merched A, Nour E, et al. Low-density lipoprotein receptor gene therapy using helper-dependent adenovirus produces long-term protection against atherosclerosis in a mouse model of familial hypercholesterolemia. Gene Ther 2004;11:1540-8 (Pubitemid 39359462)
65. Kankkonen HM, Vahakangas E, Marr RA, et al. Long-term lowering of plasma cholesterol levels in LDL-receptor-deficient WHHL rabbits by gene therapy. Mol Ther 2004;9:548-56 (Pubitemid 38578805)
66. Lebherz C, Gao G, Louboutin JP, et al. Gene therapy with novel adeno-associated virus vectors substantially diminishes atherosclerosis in a murine model of familial hypercholesterolemia. J Gene Med 2004;6:663-72 (Pubitemid 40228082)
67. Takahashi M, Ilan Y, Chowdhury NR, et al. Long term correction of bilirubin-UDP-glucuronosyltransferase deficiency in Gunn rats by administration of a recombinant adenovirus during the neonatal period. J Biol Chem 1996;271:26536-42 (Pubitemid 26359052)
68. van der Wegen P, Louwen R, Imam AM, et al. Successful treatment ofUGT1A1 deficiency in a rat model of Crigler-Najjar disease by intravenous administration of a liver-specific lentiviral vector. Mol Ther 2006;13:374-81 (Pubitemid 43056903)
69. Schmitt F, Remy S, Dariel A, et al. Lentiviral vectors that express UGT1A1 in liver and contain miR-142 target sequences normalize hyperbilirubinemia in Gunn rats. Gastroenterology 2010;139:999-1007
70. Wang X, Sarkar DP, Mani P, et al. Long-term reduction ofjaundice in Gunn rats by nonviral liver-targeted delivery of sleeping beauty transposon. Hepatology 2009;50:815-24
71. Seppen J, Bakker C, de Jong B, et al. Adeno-associated virus vector serotypes mediate sustained correction of bilirubin UDP glucuronosyltransferase deficiency in rats. Mol Ther 2006;13:1085-92 (Pubitemid 43779183)
72. Hannon GJ. RNA interference. Nature 2002;418:244-51 (Pubitemid 34773784)
73. Tomari Y, Zamore PD. Perspective: machines for RNAi. Genes Dev 2005;19:517-29 (Pubitemid 40314984)
74. Guo H, Ingolia NT, Weissman JS, et al. Mammalian microRNAs predominantly act to decrease target mRNA levels. Nature 2010;466:835-40
75. Shlomai A, Shaul Y. Inhibition of hepatitis B virus expression and replication by RNA interference. Hepatology 2003;37:764-70 (Pubitemid 36397386)
76. McCaffrey AP, Nakai H, Pandey K, et al. Inhibition of hepatitis B virus in mice by RNA interference. Nat Biotechnol 2003;21:639-44 (Pubitemid 36638090)
77. Chen Y, Cheng G, Mahato RI. RNAi for treating hepatitis B viral infection. Pharm Res 2008;25:72-86
78. Chen CC, Ko TM, Ma HI, et al. Long-term inhibition of hepatitis B virus in transgenic mice by double-stranded adeno-associated virus 8-delivered short hairpin RNA. Gene Ther 2007;14:11-19
79. Chen CC, Sun CP, Ma HI, et al. Comparative study of anti-hepatitis B virus RNA interference by double-stranded adeno-associated virus serotypes 7, 8, and 9. Mol Ther 2009;17:352-9
80. Li Z, He ML, Yao H, et al. Inhibition of HBV replication and gene expression in vitro and in vivo with a single AAV vector delivering two shRNA molecules. BMB Rep 2009;42:59-64
81. Giering JC, Grimm D, Storm TA, et al. Expression of shRNA from a tissue-specific pol II promoter is an effective and safe RNAi therapeutic. Mol Ther 2008;16:1630-6
82. Grimm D, Streetz KL, Jopling CL, et al. Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways. Nature 2006;441:537-41 (Pubitemid 44050158)
83. Grimm D, Wang L, Lee JS, et al. Argonaute proteins are key determinants of RNAi efficacy, toxicity, and persistence in the adult mouse liver. J Clin Invest 2010;120:3106-19
84. Sarbah SA, Younossi ZM. Hepatitis C: an update on the silent epidemic. J Clin Gastroenterol 2000;30:125-43 (Pubitemid 30148441)
85. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001;358:958-65 (Pubitemid 32913521)
86. Garcia-Retortillo M, Forns X. Prevention and treatment of hepatitis C virus recurrence after liver transplantation. J Hepatol 2004;41:2-10 (Pubitemid 39005145)
87. Pan QW, Henry SD, Scholte BJ, et al. New therapeutic opportunities for hepatitis C based on small RNA. WorldJ Gastroenterol 2007;13:4431-6 (Pubitemid 47412404)
88. Jopling CL, Yi M, Lancaster AM, et al. Modulation of hepatitis C virus RNA abundance by a liver-specific MicroRNA. Science 2005;309:1577-81 (Pubitemid 41266486)
89. Elmen J, Lindow M, Schutz S, et al. LNA-mediated microRNA silencing in non-human primates. Nature 2008;452:896-9 (Pubitemid 351550859)
90. Lanford RE, Hildebrandt-Eriksen ES, Petri A, et al. Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection. Science 2010;327:198-201
91. Kapadia SB, Brideau-Andersen A, Chisari FV. Interference of hepatitis C virus RNA replication by short interfering RNAs. Proc Natl Acad Sci USA 2003;100:2014-18 (Pubitemid 36254565)
92. Yokota T, Sakamoto N, Enomoto N, et al. Inhibition of intracellular hepatitis C virus replication by synthetic and vector-derived small interfering RNAs. EMBO Rep 2003;4:602-8 (Pubitemid 36939952)
93. Prabhu R, Garry RF, Dash S. Small interfering RNA targeted to stem-loop II of the 5' untranslated region effectively inhibits expression of six HCV genotypes. Virol J 2006;3:100
94. Chang B, Lee CH, Lee JH, et al. Comparative analysis of intracellular inhibition of hepatitis C virus replication by small interfering RNAs. Biotechnol Lett 2010;32:1231-7
95. Neumann AU, Lam NP, Dahari H, et al. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy. Science 1998;282:103-7 (Pubitemid 28471138)
96. Wilson JA, Richardson CD. Hepatitis C virus replicons escape RNA interference induced by a short interfering RNA directed against the NS5b coding region. J Virol 2005;79:7050-8 (Pubitemid 40677336)
97. Konishi M, Wu CH, Kaito M, et al. siRNA-resistance in treated HCV replicon cells is correlated with the development of specific HCV mutations. J Viral Hepat 2006;13:756-61 (Pubitemid 44583501)
98. Henry SD, van der Wegen P, Metselaar HJ, et al. Simultaneous targeting of HCV replication and viral binding with a single lentiviral vector containing multiple RNA interference expression cassettes. Mol Ther 2006;14:485-93 (Pubitemid 44296093)
99. Grimm D, Kay MA. Combinatorial RNAi: a winning strategy for the race against evolving targets? Mol Ther 2007;15:878-88 (Pubitemid 46621646)
100. Tacere Therapeutics. Available from: http://www.tacerebio.com/Technology/ technology.html
101. Hoti E, Adam R Liver transplantation for primary and metastatic liver cancers. Transpl Int 2008;21:1107-17
102. Hernandez-Alcoceba R, Sangro B, Prieto J. Gene therapy of liver cancer. Ann Hepatol 2007;6:5-14 (Pubitemid 46407484)
103. Pan QW, Cai R, Liu XY, et al. A novel strategy for cancer gene therapy: RNAi. Chin Sci Bull 2006;51:1145-51 (Pubitemid 44432221)
104. Pan Q, Liu B, Liu J, et al. Synergistic antitumor activity of XIAP-shRNA and TRAIL expressed by oncolytic adenoviruses in experimental HCC. Acta Oncol 2008;47:135-44
105. Kota J, Chivukula RR, O'Donnell KA, et al. Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model. Cell 2009;137:1005-17
106. Rossi JJ. New hope for a microRNA therapy for liver cancer. Cell 2009;137:990-2
107. Habib N, Salama H, Abd EL, LatifAbu Median A, et al. Clinical trial of E1B-deleted adenovirus (dl1520) gene therapy for hepatocellular carcinoma. Cancer Gene Ther 2002;9:254-9 (Pubitemid 34205499)
108. Sangro B, Mazzolini G, Ruiz M, et al. A phase I clinical trial of thymidine kinase-based gene therapy in advanced hepatocellular carcinoma. Cancer Gene Ther 2010;17:837-43
109. Penuelas I, Mazzolini G, Boan JF, et al. Positron emission tomography imaging of adenoviral-mediated transgene expression in liver cancer patients. Gastroenterology 2005;128:1787-95 (Pubitemid 40824689)
110. Pan QW, Zhong SY, Liu BS, et al. Enhanced sensitivity of hepatocellular carcinoma cells to chemotherapy with a smac-armed oncolytic adenovirus. Acta Pharmacol Sin 2007;28:1996-2004
111. Pan Q, Liu B, Liu J, et al. Synergistic induction of tumor cell death by combining cisplatin with an oncolytic adenovirus carrying TRAIL. Mol Cell Biochem 2007;304:315-23 (Pubitemid 47456880)
112. Wang Y, Huang F, Cai H, et al. The efficacy of combination therapy using adeno-associated virus-TRAIL targeting to telomerase activity and cisplatin in a mice model of hepatocellular carcinoma. J Cancer Res Clin Oncol 2010;136:1827-37
113. Yang ZX, Wang D, Wang G, et al. Clinical study of recombinant adenovirus-p53 combined with fractionated stereotactic radiotherapy for hepatocellular carcinoma. J Cancer Res Clin Oncol 2010;136:625-30
114. Tian G, Liu J, Zhou JS, et al. Multiple hepatic arterial injections of recombinant adenovirus p53 and 5-fluorouracil after transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma: a pilot phase II trial. Anticancer Drugs 2009;20:389-95
115. Li N, Zhou J, Weng D, et al. Adjuvant adenovirus-mediated delivery of herpes simplex virus thymidine kinase administration improves outcome of liver transplantation in patients with advanced hepatocellular carcinoma. Clin Cancer Res 2007;13:5847-54 (Pubitemid 47583910)
116. Ishibashi H, Nakamura M, Komori A, et al. Liver architecture, cell function, and disease. Semin Immunopathol 2009;31:399-409
117. Nemeth E, Baird AW, O'Farrelly C. Microanatomy of the liver immune system. Semin Immunopathol 2009;31:333-43
118. Demirkiran A, Bosma BM, Kok A, et al. Allosuppressive donor CD4+CD25+ regulatory T cells detach from the graft and circulate in recipients after liver transplantation. J Immunol 2007;178:6066-72 (Pubitemid 46717386)
119. Bosma BM, Metselaar HJ, Mancham S, et al. Characterization of human liver dendritic cells in liver grafts and perfusates. Liver Transpl 2006;12:384-93
120. Crispe IN. The liver as a lymphoid organ. Annu Rev Immunol 2009;27:147-63
121. Calne RY, Sells RA, Pena JR, et al. Induction of immunological tolerance by porcine liver allografts. Nature 1969;223:472-6
122. Kamada N, Wight DG. Antigen-specific immunosuppression induced by liver transplantation in the rat. Transplantation 1984;38:217-21 (Pubitemid 14035167)
123. McCaffrey AP, Fawcett P, Nakai H, et al. The host response to adenovirus, helper-dependent adenovirus, and adeno-associated virus in mouse liver. Mol Ther 2008;16:931-41 (Pubitemid 351587104)
124. Hensley SE, Amalfitano A. Toll-like receptors impact on safety and efficacy of gene transfer vectors. Mol Ther 2007;15:1417-22 (Pubitemid 47099298)
125. Zhang Y, Chirmule N, Gao G, et al. CD40 ligand-dependent activation of cytotoxic T lymphocytes by adeno-associated virus vectors in vivo: role of immature dendritic cells. J Virol 2000;74:8003-10 (Pubitemid 30641645)
126. LoDuca PA, Hoffman BE, Herzog RW. Hepatic gene transfer as a means of tolerance induction to transgene products. Curr Gene Ther 2009;9:104-14
127. Dobrzynski E, Fitzgerald JC, Cao O, et al. Prevention of cytotoxic Tlymphocyte responses to factor IX-expressing hepatocytes by gene transfer-induced regulatory T cells. Proc Natl Acad Sci USA 2006;103:4592-7
128. Mingozzi F, Hasbrouck NC, Basner-Tschakarjan E, et al. Modulation of tolerance to the transgene product in a nonhuman primate model of AAV-mediated gene transfer to liver. Blood 2007;110:2334-41 (Pubitemid 47523153)
129. Mingozzi F, Maus MV, Hui DJ, et al. CD8+ T-cell responses to adeno-associated virus capsid in humans. Nat Med 2007;13:419-22 (Pubitemid 46559826)
130. Pien GC, Basner-Tschakarjan E, Hui DJ, et al. Capsid antigen presentation flags human hepatocytes for destruction after transduction by adeno-associated viral vectors. J Clin Invest 2009;119:1688-95
131. Erles K, Sebokova P, Schlehofer JR Update on the prevalence of serum antibodies (IgG and IgM) to adeno-associated virus (AAV). J Med Virol 1999;59:406-11 (Pubitemid 29468085)
132. Blacklow NR, Hoggan MD, Rowe WP. Serologic evidence for human infection with adenovirus-associated viruses. J Natl Cancer Inst 1968;40:319-27
133. Parks WP, Boucher DW, MelnickJL, et al. Seroepidemiological and ecological studies of the adenovirus-associated satellite viruses. Infect Immun 1970;2:716-22
134. Calcedo R, Vandenberghe LH, Gao G, et al. Worldwide epidemiology of neutralizing antibodies to adeno-associated viruses. J Infect Dis 2009;199:381-90
135. Boutin S, Monteilhet V, Veron P, et al. Prevalence of serum IgG and neutralizing factors against adeno-associated virus (AAV) types 1, 2, 5, 6, 8, and 9 in the healthy population: implications for gene therapy using AAV vectors. Hum Gene Ther 2010;21:704-12
136. Vandenberghe LH, Wang L, Somanathan S, et al. Heparin binding directs activation of T cells against adeno-associated virus serotype 2 capsid. Nat Med 2006;12:967-71 (Pubitemid 44175151)
137. Davidoff AM, Gray JT, Ng CY, et al. Comparison of the ability of adeno-associated viral vectors pseudotyped with serotype 2, 5, and 8 capsid proteins to mediate efficient transduction of the liver in murine and nonhuman primate models. Mol Ther 2005;11:875-88 (Pubitemid 40724106)
138. Huttner NA, Girod A, Perabo L, et al. Genetic modifications of the adeno-associated virus type 2 capsid reduce the affinity and the neutralizing effects of human serum antibodies. Gene Ther 2003;10:2139-47 (Pubitemid 37536764)
139. Maheshri N, Koerber JT, Kaspar BK, et al. Directed evolution of adeno-associated virus yields enhanced gene delivery vectors. Nat Biotechnol 2006;24:198-204 (Pubitemid 43221704)
140. Maersch S, Huber A, Buning H, et al. Optimization of stealth adeno-associated virus vectors by randomization of immunogenic epitopes. Virology 2010;397:167-75
141. Jiang H, Couto LB, Patarroyo-White S, et al. Effects of transient immunosuppression on adenoassociated, virus-mediated, liver-directed gene transfer in rhesus macaques and implications for human gene therapy. Blood 2006;108:3321-8
142. Arruda VR, Stedman HH, Haurigot V, et al. Peripheral transvenular delivery of adeno-associated viral vectors to skeletal muscle as a novel therapy for hemophilia B. Blood 2010;115:4678-88
143. Wang Z, Allen JM, Riddell SR, et al. Immunity to adeno-associated virus-mediated gene transfer in a random-bred canine model of Duchenne muscular dystrophy. Hum Gene Ther 2007;18:18-26 (Pubitemid 46105461)
144. Wang Z, Kuhr CS, Allen JM, et al. Sustained AAV-mediated dystrophin expression in a canine model of Duchenne muscular dystrophy with a brief course of immunosuppression. Mol Ther 2007;15:1160-6 (Pubitemid 46813619)
145. Yuasa K, Yoshimura M, Urasawa N, et al. Injection of a recombinant AAV serotype 2 into canine skeletal muscles evokes strong immune responses against transgene products. Gene Ther 2007;14:1249-60 (Pubitemid 47299950)
146. Halbert CL, Madtes DK, Vaughan AE, et al. Expression of human alpha1-antitrypsin in mice and dogs following AAV6 vector-mediated gene transfer to the lungs. Mol Ther 2010;18:1165-72
147. Nash KL, Jamil B, Maguire AJ, et al. Hepatocyte-specific gene expression from integrated lentiviral vectors. J Gene Med 2004;6:974-83 (Pubitemid 40228112)
148. Kramer MG, Barajas M, Razquin N, et al. In vitro and in vivo comparative study of chimeric liver-specific promoters. Mol Ther 2003;7:375-85 (Pubitemid 36503861)
149. Brown BD, Naldini L. Exploiting and antagonizing microRNA regulation for therapeutic and experimental applications. Nat Rev Genet 2009;10:578-85
150. Brown BD, Venneri MA, Zingale A, et al. Endogenous microRNA regulation suppresses transgene expression in hematopoietic lineages and enables stable gene transfer. Nat Med 2006;12:585-91
151. Brown BD, Cantore A, Annoni A, et al. A microRNA-regulated lentiviral vector mediates stable correction of hemophilia B mice. Blood 2007;110:4144-52 (Pubitemid 351377775)
152. Golshayan D, Pascual M. Tolerance-inducing immunosuppressive strategies in clinical transplantation: an overview. Drugs 2008;68:2113-30
153. Pan Q, Metselaar HJ, de Ruiter P, et al. Calcineurin inhibitor tacrolimus does not interfere with the suppression of hepatitis C virus infection by interferon-alpha. Liver Transpl 2010;16:520-6
154. Tjon AS, Nicolaas JS, Kwekkeboom J, et al. Increased incidence of early de novo cancer in liver graft recipients treated with cyclosporine: an association with C2 monitoring and recipient age. Liver Transpl 2010;16:837-46
155. Watashi K, Hijikata M, Hosaka M, et al. Cyclosporin A suppresses replication of hepatitis C virus genome in cultured hepatocytes. Hepatology 2003;38:1282-8 (Pubitemid 37314838)
156. Henry SD, Metselaar HJ, Lonsdale RC, et al. Mycophenolic acid inhibits hepatitis C virus replication and acts in synergy with cyclosporin A and interferon-alpha. Gastroenterology 2006;131:1452-62 (Pubitemid 44708933)